Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be8e0da1b314bf83e52dfe44a1e14f12 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
filingDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d12765e06b7c0d249c10e3e31fd86942 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab2b482cbd3b2bba845d0c227c6a10d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20409e1425a94d1bb44f91e80e36b0a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9015a1b1a0f43563a5e635541040f7ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c72b62de45e2619475ed525874a4982a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32b01106a096c5393e98c9f2579c65e5 |
publicationDate |
2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11021531-B1 |
titleOfInvention |
Anti-SARS-Cov-2 antibodies derived from 2GHW |
abstract |
This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11732030-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11740240-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114231497-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7343739-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023044397-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022018838-A1 |
priorityDate |
2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |